IPO subscription opens as red herring prospectus lists multiple lawsuits

The IPO subscription window for Symbiotech Pharmalab began on Monday, offering investors a chance to buy shares within a Rs 938‑Rs 988 price range. The prospectus openly lists ongoing criminal, tax and civil matters against directors, the promoter group and subsidiaries. It cautions that any unfavorable judgment—whether in one case or cumulatively—could have a detrimental impact on the firm’s market standing, managerial stability, operational results, balance‑sheet strength and cash‑flow generation.